SCHEMBL5536247

SCHEMBL5536247

CCc1ccc(CCNc2cc[c]cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.46
MAPT P10636 2/20 0.44
GPR84 Q9NQS5 2/20 0.43
CXCR4 P61073 1/20 0.42
TAAR1 Q96RJ0 2/20 0.41
MEN1 O00255 1/20 0.41
APAF1 O14727 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548437 0.89 L3MBTL1 (0.40) L3MBTL1MAPTGPR84CXCR4TAAR1
SCHEMBL5542122 0.89 L3MBTL1 (0.46) L3MBTL1MAPTTAAR1MEN1ALDH1A1
SCHEMBL5548284 0.85 MAPT (0.60) L3MBTL1MAPTGPR84TAAR1MEN1
SCHEMBL5542245 0.83 TAAR1 (0.52) L3MBTL1MAPTGPR84TAAR1HPGD
SCHEMBL5542666 0.82 GPR84 (0.48) L3MBTL1MAPTGPR84KCNH2
SCHEMBL5543154 0.81 TAAR1 (0.50) L3MBTL1MAPTGPR84TAAR1MEN1
SCHEMBL5539704 0.81 GPR84 (0.50) L3MBTL1MAPTGPR84TAAR1MEN1
SCHEMBL5546151 0.81 MEN1 (0.61) L3MBTL1MAPTCXCR4MEN1APAF1
SCHEMBL5544020 0.81 L3MBTL1 (0.70) L3MBTL1MAPTTAAR1MEN1ALDH1A1
SCHEMBL7223359 0.81 MAPT (0.69) MAPTTAAR1ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885MAPT 4117/4885GPR84 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.